Quarterly Activities/Appendix 4C Cash Flow Report

• Initial U.S. sites are now serving as reference sites to demonstrate the clinical value of our diagnostic solution, to support the acquisition of additional customers; • UK revenue was underpinned by improving gastroenteric sales performance, reflecting growing momentum with National Health Service (NHS) clientele; • Continued progress on the development of an automated, high-throughput solution